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Session
Objectives

1. Select appropriate candidates for

SMART therapy and successfully
formulate a SMART-based asthma
action plan

2. Anticipate barriers to implementation of

new SMART guidelines on both
individual and institutional levels

3. Generate an actionable plan, tailored

to participants’ care settings, to begin
implementation of SMART

What is
SMART?
• One inhaler for both controller
and rescue:
Inhaled corticosteroid (ICS)
+
Long acting beta agonist (LABA)

EPR-4 Guideline Update
•

Published in December 2020
EPR - Expert Panel Report
NAEPCC - National Asthma Education and Prevention Program
Coordination Committee
NHLBI - National Heart, Lung, and Blood Institute

•

Series of recommended practice updates – some very relevant to
PHM practice

EPR-4 Recommendations – Section IV
EPR-3 (2007)
0-4 years of age:
mild symptoms or
recurrent wheezing:
SABA q 4-6 hrs for 24
hrs, for more than 24
hrs, need evaluation

EPR-4 (2020)
EPR-4 Recommendations

Clinical scenario
0-4 years of age:
- Recurrent wheezing
with viral illnesses:

Short course of ICS + PRN SABA at onset of
respiratory illness (Conditional)

> 4 years of age:
- Mild/moderate
persistent asthma:

Recommend against short term increase
in ICS dose (Conditional)

- Mod/severe
persistent asthma:

Low or moderate dose ICS/formoterol as
daily and quick relief therapy compared to
ICS/LABA + PRN SABA or high dose ICS +
PRN SABA (Strong)

EPR-4 Recommendations – Section IV
EPR-3 (2007)

Clinical scenario

>12 years of age:
>12 years of age:
-daily ICS for persistent - Mild persistent
asthmatics with
asthma:
low/med/high dosing
based on severity with
- Mod/severe
use of SABA prn for all
persistent asthma:
steps.
- consideration of
medium dose ICS/LABA
at Step 4 (mod/severe)

EPR-4 (2020)
EPR-4 Recommendations
Daily low dose ICS + PRN SABA or option of
adding ICS to PRN SABA at illness
(Conditional)
ICS/formoterol as daily and quick reliever
therapy compared to higher dose ICS/LABA
as daily with PRN SABA (Conditional)

Our focus: SMART-specific recommendations
Clinical scenario
0-4 years of age:
- Recurrent wheezing with viral
illnesses:
> 4 + years of age:
- Mild/moderate persistent
asthma:
- Mod/severe persistent
asthma:
>12+ years of age:
- Mild persistent asthma:

EPR-4 (2020)
EPR-4 Recommendations
Short course of ICS + PRN SABA at onset of respiratory illness
(Conditional)
Recommend against short term increase in ICS dose (Conditional)
Low or moderate dose ICS/formoterol as daily and quick relief therapy
compared to ICS/LABA + PRN SABA or high dose ICS + PRN SABA
(Strong)

Daily low dose ICS + PRN SABA or option of adding ICS to PRN SABA at
illness (Conditional)
- Mod/severe persistent asthma: ICS/formoterol as daily and quick reliever therapy compared to higher
dose ICS/LABA as daily with PRN SABA (Conditional)

It is critical for
hospitalists to understand
the updated EPR-4
guidelines, but also to
IMPLEMENT them
But…. How?

How to Participate in
Audience Polling
Navigate to https://phm.cnf.io and tap the
session titled "Get SMART: Implementation of
Updated Asthma Guidelines for Pediatric
Hospitalists"
OR just point your phone’s camera at the QR
code to join directly

Have you ever started
SMART?

Live Content Slide
When playing as a slideshow, this slide will display live content

Poll: Have you ever started SMART?

Single Maintenance and Reliever Therapy
(SMART)
Step 2
ICS only
Patient having
frequent
exacerbations
e.g. compliant with
Flovent 44 BID

Step 3
Change to
Medium
Dose ICS
+LABA

Single Maintenance and Reliever Therapy
(SMART)
Step 2
ICS only
Patient having
frequent
exacerbations
e.g. compliant with
Flovent 44 BID

Single Maintenance and Reliever Therapy
(SMART)
Step 2
ICS only
Patient having
frequent
exacerbations
e.g. compliant with
Flovent 44 BID

SMART
LABA+ICS
Daily AND
1-2 puffs prn
(max doses
by age)

Which patients to
consider?
Target Population:

•
•
•

Moderate to Severe
Persistent Asthma ≥ Age 4
Severe exacerbation in the
prior year
Uncontrolled on ICS LABA
with prn SABA

Which patients to consider?
• Who should not receive this treatment: Do not use
ICS-formoterol as reliever therapy in individuals taking
ICS-salmeterol as maintenance therapy.

Benefits & Risks
Potential benefits:
● Reduced asthma exacerbations
○
○

Unscheduled medical visits
Systemic corticosteroids

● Improved asthma control and
quality of life
● In children ages 4–11 years, there
may be a lower risk of growth
suppression among those taking
SMART versus daily higher-dose ICS
treatment!

Potential risks:
●

No difference in harms
between SMART and daily
ICS, or ICS-LABA, with SABA
PRN

Implementing SMART Therapy
Age

Budesonide/
formoterol
dose

4-11
Maintenance

Moderate Persistent
Step 3

INSERT TABLE MC TO DO

1 puff daily

Step 4
1 puff bid

80 µg/4.5
Relief
12+
Maintenance

8
1 puff prn

1 puff prn

1 bid or 2 puffs daily

2 puffs bid

160µg/4.5
Relief
Total daily ICS

Max
puffs/
day

12
1 puff prn

1 puff prn

< 400 µg/day
(medium)

400-800 µg/day
(high)

Disclaimer
● Budesonide/formoterol (Symbicort)
○ Most studied for SMART therapy
○ Approved age 8 and above in US for
maintenance
● Mometasone/formoterol (Dulera)
○ Approved age 5 and above in US for
maintenance

1-month supply of ICSformoterol medication
that is sufficient for
maintenance therapy
may not last a month if
the inhaler is used for
reliever therapy as
well.

Via The Journal of Allergy and Clinical Immunology: In Practice 2022 10S31-S38DOI: (10.1016/j.jaip.2021.10.011)

Successful Prescribing
Budesonide/formoterol
(Symbicort) 80/4.5

Sig: 1 puff daily and then 1-2 puffs
as needed for up to 6 additional
puffs (max of 8 total puffs per day)
Dispense: 1 for home, 1 for school

Budesonide/formoterol
(Symbicort) 160/4.5

Sig: Maintenance 2 puffs daily
Dispense 60
Sig: Reliever 1-2 puffs prn up to
7 inhalations per day
Dispense 120

Outpatient exacerbation management
● Anticipatory guidance
○ Ensure families understand not just to start nebulizing albuterol
○ Summarize data for them to enhance partnership
● “Sick Plan”
○ 1-2 puffs ICS/LABA every 5-10 minutes (with age appropriate max)
● Increasing therapy
○ Patients should call if exceeding daily puff max
○ Patients should call if using max puffs for more than 2-3 days
■ Oral Steroids 1 mg/kg bid (max of 30 mg bid)

When SMART fails
● Review MDI/Spacer technique
● Ensure family understands SMART
○ If unable to execute switch to alternative pathway (traditional plan)
● Have family keep journal/calendar of therapy
● Referral to allergy or pulmonology
○ Consideration of biologic therapy
○ Implementation of high dose inhaled ICS therapy
○ Implementation of oral corticosteroid therapy

“OK, yeah I guess can do that.
But it’s just so hard to change.”
From individual understanding and use, to moving a group to implement
something new; change is hard

The implementation lag:
17 years to incorporate research into common
clinical practice
-Morris et al 2011
17 years ago this year
Brad and Jen Divorced
Hurricane Katrina
Destiny’s Child broke up
Lance won the Tour de France, (7 years later was stripped of the win)
The Office premiered
First complete genome of a dog published

Ashrafzedah et al 2019

Implementation
science (IS)
“The study of methods to
promote the adoption and
integration of evidence-based
practices, interventions and
policies into routine health care
and public health settings.”
Fogarty International Center. Implementation science
information and resources, https://www-fic-nihgov.ezproxy.cmh.edu/ResearchTopics/Pages/Impleme
ntationScience.aspx/; 2019.

Implementation and QI:
two paths with same goal
• Implementation: closes gap
between what is known and
what is practiced
• QI: transforms systems to
improve health care quality
Common differences:
1) Starting point
2) scope/scale of goals
3) perspective
Tyler and Glasgow, Hospital Pediatrics 2021

Pre-implementation work:
Stakeholders
•Patients/Families
•Providers
•Hospitals, EDs, UCs
•Schools
•Insurance
•Pharmacies
•Community Asthma
Organizations

Organization & Local
contexts
•Emergency Rooms
•Urgent Cares
•Hospital Medicine
•Allergy/Immunology
•Pulmonology
•Primary Care Clinics
•Adolescent Clinics

Providers
•PCPs
•Hospitalists
•Specialists
•Trainees
•Pharmacists
•RTs

Economic & Social
Environment
•Insurance coverage
•Outreach structures to
community providers and
schools

Identifying performance/outcome gaps:
CMH Providers “Regularly prescribing”
ICS-LABA, Prior to EPR-4 release

Asthma Guidelines Used at CMH

100.00%

100.00%

66.70%
57.10%

32.10%

26.00%

18.37%

Asthma
specialists

UC/ED
None

Primary care
NHLBI/GINA

Trainee

Secondary Guideline

Hospitalists

specialist

non-asthma specialists

14.29%

trainee

Environment

People

Multi-disciplinary care

Provider
culture

Encounter Time

Practice inertia

Patient/family preferences
Guideline knowledge

Outcome expectancy
Acute Care Role

Other references

Resident Clinics
EHR
Change of service

Guideline challenges
Community PCP
Medication options

Materials

Processes

Equipment

Guidelineadherent
AAPs &
SMART
therapy
implement
ation
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Common Barriers to Guideline Use
Internal (Provider)
External:
• Guideline related
• Patient Related
• Institutional/Environment
• Time
• Team
• Tools

Equity

What are barriers you foresee to
implementing SMART or other
EPR-4 guidelines in your
practice as a hospitalist?
Free text response from audience

Live Content Slide
When playing as a slideshow, this slide will display live content

Poll: What are barriers you foresee to implementing
SMART or other EPR-4 guidelines in your practice as
a hospitalist?

Physician Level Barriers
Cabana and Flores, 2002

Provider-level barriers
Lack of awareness and familiarity (good
working knowledge)
Lack of agreement with guideline
conclusion, appropriateness
Lack of self efficacy
The feeling of capable of effective use
of guideline)
Lack of outcome expectancy
Don’t expect real-world results for
their patients
Inertia of previous practice
Cabana et al. 1999

External Barriers
Guideline related
• No convenient access
to guideline
• Cumbersome to
reference
• Confusing or at odds
with other guidelines

Patient Related
• Difficult to understand
• Difficult to adhere to
• Inertia to change
• Don’t believe benefits >
risk

Institutional

Resources/Financial

• Time to familiarize,
access regularly,
counsel families
• RT and nurse lack of
familiarity

• Insurance coverage for
non-FDA approved
ages
• Insurance coverage of
increased use

• Trainee/attending dyssynchronous adoption
• Multi-disciplinary
provision of asthma
care
• Internal clinical
guideline consistency
• Prescribing ease
• EMR tools

• No alternatives to
formoterol

• Continuity within
system

Equity of the new guidelines
Race/ethnicity group
Asian
Black
Hispanic
American Indian, Alaskan Native,
Native Hawaiian, Pacific Islander
White
Other/Unknown
Total

Pediatric only
(6 studies)
0
63 (4.2%)
0
0

Pediatric and adult
(3 studies)
3090 (8.1%)
3462 (9.1%)
0
1160 (3.1%)

1057 (71.2%)
364 (24.5%)
1484

28341 (74.7%)
1902 (5.0%)
37955

Adah and Jones, unpublished

Frameworks:
Playbook for Dissemination
& Implementation
• Selected based on outcomes,
context and barriers
• Pragmatic, guided description
of domains, factors, resources
• Allows the users to
systematically address needs
during implementation

What resources or tools do
you feel are important when
implementing practice
changes at your hospital?

Live Content Slide
When playing as a slideshow, this slide will display live content

Poll: What resources or tools do you feel are
important when implementing practice changes at
your hospital?

Clinical pathways

Clinical pathways

Institutional guides

Institutional guides

Institutional resources

Grand rounds/division
meetings
• #ThatZoomLife
ALEX

• Give division updates
• Demonstrate expertise to
community groups

Asynchronous medical education

The Journal of Allergy and Clinical Immunology: In Practice (January 2022)
DOI: 10.1016/j.jaip.2021.10.011

Logistics – SMART
Asthma Action Plan

Logistics – Insurance
Coverage
Problem: Insurance companies
have not caught up with the
current practice guidelines
Insurance typically covers
ICS/LABA dosing at the
traditional rate of 1-2 puffs BID
Patients use more often with
SMART, run out faster

• Solutions:
○

○

Prescribing work-arounds (e.g.
prescribing a higher dose ICS/LABA, but
just 1 puff at a time)
Working with insurance
companies/representatives who can
enact change

Logistics - Care
Coordination
1. Patients leave the hospital with
a new (and possibly very
different/less familiar) AAP
2. PCPs, schools and other
providers need to be aware of the
new plan, the new recommended
guidelines, AND buy into this plan
for their patient to continue in the
future

Solutions

• Developing standard language for discharge
summaries accompanying the SMART AAP that
explains the new plan and and EPR-4
recommendations, with references

Children’s Mercy experience

• Educational Outreach to CMH-associated PCP
clinics:
• Local educational newsletters
• Outward-facing Asthma Resource Guide

QI and IS tools for
implementing SMART

Resources for choosing a Framework
Dissemination-implementation.org

Cause-Effect Diagram: QI and PRISM framework
Guideline use Culture
People

Organizational
characteristics

Organizational
Priorities

Environment

Adoption of
SMART therapy

Materials

Methods

Equipment

Implementation
infrastructure

Organizational
Culture

External
Environment

Measuring Outcomes
Quantitative

Qualitative

SMART AAP ordering

Provider satisfaction

SMART education provided by physicians/RTs

Community provider satisfaction with hospitalmade change to SMART

ICS/LABA orders within the hospital

Patient and family satisfaction with change to
SMART

Provider reported knowledge of guidelines
OUTCOMES

Balancing Measures

Asthma control scores (within system)

Length of stay/ Visit due to SMART education

Exacerbations

Patient inability to attain medication (insurance
coverage)

Patient reported ICS daily use

v

*

Implementation
outcome measures
Variation between guideline or
Appropriateness for a population

*

E.g., Are we not implementing down to 4 yo
because of patient barriers, or insurance/FDA
barriers?

Ashrafzedah et al 2019

Question:
What outcome measures do you think could
be easily tracked at your institution or could
help to evaluate for effective implementation?

SMART
Implementation
Resources/Toolkit

Final
Thoughts

•

Pediatric hospitalists can proactively initiate SMART
in the hospital setting

•

Sustainable implementation of EPR-4 SMART
guidelines starts with assessment of:
• Care gaps
• Environments
• Barriers

•

Involve all relevant stakeholders early in the
process

•

Dissemination & Implementation tools should be
used to address barriers at many levels
• Audit for successful sustained use

Alex Hogan:
AHogan@connecticutchildrens.org
@AlexHoganMD
Kate Kyler:

Thank you!

Please reach out with any questions

kekyler@cmh.edu
@kedkyler
Claire Seguin:
cmseguin@gmail.com

SMART
Implementation
Resources/Toolkit

